THE USE OF INTERFERON ALPHA IN
THERAPY OF CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA IN CHILDREN
H. Hrstkova, M. Bajer, J.
Michálek
The First Paediatric Internal
and Oncological Clinic, Medical Fac. MU, Brno, Czech Republic
OBJECTIVE. Treatment of
chronic immune thrombocytopenic purpura (ITP) is barely effective, but
promising results of interferon alpha therapy were reported recently.
METHODS. In a prospective
study, 28 children between 4 and 18 years of age with chronic ITP were treated
by recombinant human interferon alpha 2a (rh INFa-2a) with a single dose of
3MU/m2 three times a week for 4-5 weeks (1 cycle).
RESULTS. Very good
(platelets > 100 x 109/l in peripheral blood) and good (50-100 x 109/l)
therapeutic responses at the end of rh INFa-2a therapy were reached in 12
(42.8%) and 10 (35.7%) out of 28 patients, respectively. After 6 months of
follow-up 18 out of 26 (69.2%) evaluable patients sustained in very good or
good therapeutic response. In 11 evaluable patients after 12 months of
follow-up 8 (72.7%) were in very good or good therapeutic response. 11 out of
28 children had severe chronic ITP with platelets < 20 x 109/l and 6 (54.6%)
of them showed good or very good response at the end of interferon alpha cycle
and 5 (45.5%) sustained in very good or good response for 6 months. Repeated
cycles or interferon alpha therapy were administered to 8 poor responders
(platelets < 50 x 109/l) with very good or good response lasting for at
least 6 months in 6 (75%) of them. Frequent side effect of interferon alpha is
transient fever, less frequently flu-like syndrome may by present.
CONCLUSIONS. It is apparent
that interferon alpha is an effective therapeutic approach to children with
chronic ITP with minimum side effects, leading frequently to sustained
remission of the disease.